These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 29660282)

  • 21. Fluorinated matrix metalloproteinases inhibitors--Phosphonate based potential probes for positron emission tomography.
    Beutel B; Daniliuc CG; Riemann B; Schäfers M; Haufe G
    Bioorg Med Chem; 2016 Feb; 24(4):902-9. PubMed ID: 26810711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hydroxamate-Based Selective Macrophage Elastase (MMP-12) Inhibitors and Radiotracers for Molecular Imaging.
    Gona K; Toczek J; Ye Y; Sanzida N; Golbazi A; Boodagh P; Salarian M; Jung JJ; Rajendran S; Kukreja G; Wu TL; Devel L; Sadeghi MM
    J Med Chem; 2020 Dec; 63(23):15037-15049. PubMed ID: 33206510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.
    Wagner S; Breyholz HJ; Law MP; Faust A; Höltke C; Schröer S; Haufe G; Levkau B; Schober O; Schäfers M; Kopka K
    J Med Chem; 2007 Nov; 50(23):5752-64. PubMed ID: 17956082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroPET Evaluation of a Hydroxamate-Based MMP Inhibitor, [(18)F]FB-ML5, in a Mouse Model of Cigarette Smoke-Induced Acute Airway Inflammation.
    Matusiak N; van Waarde A; Rozeveld D; van Oosterhout AJ; Heijink IH; Castelli R; Overkleeft HS; Bischoff R; Dierckx RA; Elsinga PH
    Mol Imaging Biol; 2015 Oct; 17(5):680-7. PubMed ID: 25822732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Matrix metalloproteinase inhibitors: a patent review (2011 - 2013).
    Li NG; Tang YP; Duan JA; Shi ZH
    Expert Opin Ther Pat; 2014 Sep; 24(9):1039-52. PubMed ID: 25098768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.
    Senn N; Ott M; Lanz J; Riedl R
    J Med Chem; 2017 Dec; 60(23):9585-9598. PubMed ID: 28953404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on γ-fluorinated α-sulfonylaminohydroxamic acid.
    Hugenberg V; Behrends M; Wagner S; Hermann S; Schäfers M; Kolb HC; Szardenings K; Walsh JC; Gomez LF; Kopka K; Haufe G
    EJNMMI Radiopharm Chem; 2018 Dec; 3():10. PubMed ID: 30101186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An integrated structure- and pharmacophore-based MMP-12 virtual screening.
    Ramezani M; Shamsara J
    Mol Divers; 2018 May; 22(2):383-395. PubMed ID: 29423648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology.
    El Ashry ESH; Awad LF; Teleb M; Ibrahim NA; Abu-Serie MM; Abd Al Moaty MN
    Bioorg Chem; 2020 Mar; 96():103616. PubMed ID: 32032847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and biological evaluation of carbon-11 and fluorine-18 labeled tracers for in vivo visualization of PDE10A.
    Ooms M; Celen S; Koole M; Langlois X; Schmidt M; De Angelis M; Andrés JI; Verbruggen A; Van Laere K; Bormans G
    Nucl Med Biol; 2014 Sep; 41(8):695-704. PubMed ID: 25002365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.
    Nara H; Sato K; Kaieda A; Oki H; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    Bioorg Med Chem; 2016 Dec; 24(23):6149-6165. PubMed ID: 27825552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of the binding interaction between fluorinated matrix metalloproteinase inhibitors and Human Serum Albumin.
    Digilio G; Tuccinardi T; Casalini F; Cassino C; Dias DM; Geraldes CF; Catanzaro V; Maiocchi A; Rossello A
    Eur J Med Chem; 2014 May; 79():13-23. PubMed ID: 24704692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo imaging of matrix metalloproteinase 12 and matrix metalloproteinase 13 activities in the mouse model of collagen-induced arthritis.
    Lim NH; Meinjohanns E; Bou-Gharios G; Gompels LL; Nuti E; Rossello A; Devel L; Dive V; Meldal M; Nagase H
    Arthritis Rheumatol; 2014 Mar; 66(3):589-98. PubMed ID: 24574219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer.
    Zhong Y; Lu YT; Sun Y; Shi ZH; Li NG; Tang YP; Duan JA
    Expert Opin Drug Discov; 2018 Jan; 13(1):75-87. PubMed ID: 29088927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New matrix metalloproteinase inhibitors based on γ-fluorinated α-aminocarboxylic and α-aminohydroxamic acids.
    Behrends M; Wagner S; Kopka K; Schober O; Schäfers M; Kumbhar S; Waller M; Haufe G
    Bioorg Med Chem; 2015 Jul; 23(13):3809-18. PubMed ID: 25921268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Development of Novel Nuclear Medical Imaging Probes for Quantification of Matrix Metalloproteinases in Diseases].
    Kondo N
    Yakugaku Zasshi; 2020; 140(1):7-13. PubMed ID: 31902888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.
    Adhikari N; Halder AK; Mallick S; Saha A; Saha KD; Jha T
    Bioorg Med Chem; 2016 Sep; 24(18):4291-4309. PubMed ID: 27452283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and preclinical evaluation of novel
    Spoelstra GB; Blok SN; Reali Nazario L; Noord L; Fu Y; Simeth NA; IJpma FFA; van Oosten M; van Dijl JM; Feringa BL; Szymanski W; Elsinga PH
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2583-2596. PubMed ID: 38644432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Matrix metalloproteinase-12 inhibitors: synthesis, structure-activity relationships and intestinal absorption of novel sugar-based biphenylsulfonamide carboxylates.
    Cuffaro D; Camodeca C; D'Andrea F; Piragine E; Testai L; Calderone V; Orlandini E; Nuti E; Rossello A
    Bioorg Med Chem; 2018 Dec; 26(22):5804-5815. PubMed ID: 30429099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors.
    Chen C; Yang X; Fang H; Hou X
    Eur J Med Chem; 2019 Nov; 181():111563. PubMed ID: 31415980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.